YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
BioCryst Pharmaceuticals, Inc. —Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX…
Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic's Claude AI recently…
Beneath the headline-driven sentiment of biotech investing lies the true engine of value creation: portfolio durability, capital efficiency, and sustainable revenue compounding. Founded on the promise of structure-based drug design, BioCry…
After its most recent pullback, biopharmaceutical stock BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) bounced off the $8 level and has now reclaimed the 320-day moving average -- both of which have been key lines of pressure and support. Furt…
M&A activity in the biotech sector has accelerated sharply in 2026, as large drugmakers increasingly turn to external innovation to strengthen pipelines, expand into new therapeutic areas and gain access to promising technologies and late-…
On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), now consistently profitable on the strength of its hereditary angioedema drug "Orladeyo," is looking to acquire more rare disease treatments, according to…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare stocks continue to attract investor attention as managed care providers, pharmaceutical companies, biotech…
Shares of Pharvaris PHVS have gained 10% over the past month, due to the positive top-line data announced on Sept. 8, 2026, from the pivotal phase III CHAPTER-3 study, which evaluated its lead drug candidate, deucrictibant's extended-relea…
BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the share price at US$8.12, with the stock down over the past week and month but modestly higher year to date. Recent trading tells a mixed story for BioCr…
Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index shedding 0.2% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
CareMed Specialty Pharmacy NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo® (berotralstat), a plasma kalli…
Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Marc Lichtenfeld of the Oxford Club highlights three healthcare plays across different time horizons: Moderna for traders, Pharvaris for the next year, and AbbVie…
The recent breakout of Moderna reminded investors that AI stocks aren't the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey'…
BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Health…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has BioCryst Pharmaceuticals (BCRX) been one of those stocks this year? By taking a look at the stock's year-to-date perfor…
BioCryst Pharmaceuticals (BCRX) closed the last trading session at $9.87, gaining 6.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. T…
BioCryst Pharmaceuticals, Inc. — Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan — RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuti…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioCryst Pharmaceuticals (BCRX) is back in focus after raising its…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. BioCryst Pharmaceuticals stock has put up a 53.0% gain over the past three years, yet the current v…
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Charlie Gayer Chief R&D Officer - Dr. Sandeep Menon Chief Financial Officer - Babar Ghias Full Conference…
Shares of BioCryst Pharmaceuticals (BCRX) have gained 6.2% over the past four weeks to close the last trading session at $10.34, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts…
Investors in BioCryst Pharmaceuticals, Inc. BCRX need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2026 $2 Put had some of the highest implied volatility of all equity options…
Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchis…
This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Completed enrollment of the largest blinded heredi…
BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Operational Pivot Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's…
Earnings Call Insights: BioCryst Pharmaceuticals (BCRX) Q2 2026 MANAGEMENT VIEW * "During the second quarter, we continued to execute effectively on the commercial and development fronts. We completed the integration of Astria Therapeutics…
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurr…
BioCryst Pharmaceuticals, Inc. — Total net revenue of $218.3 million and ORLADEYO® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO r…
Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Eli Lilly and Company (LLY [https://seekingalpha.com/symbol/LLY]) * Shopify (SHOP [https://seekingalpha.c…
BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesda…
BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) ("BioCryst" or the "Company") today announced the appointment of David W. Jenkins, MA, PhD, to the…
Shares of BioCryst Pharmaceuticals (BCRX) have gained 9.4% over the past four weeks to close the last trading session at $9.91, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts a…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioCryst Pharmaceuticals stock has delivered a 54.7% return over th…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioCryst Pharmaceuticals (NasdaqGS:BCRX) is ending its internal dis…
BioCryst Pharmaceuticals (BCRX) shares ended the last trading session 8.1% higher at $10.99. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 20.6…